Neurofibromatosis Type-2 Market

DelveInsight’s ‘Neurofibromatosis Type-2 (NF2)– Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Neurofibromatosis Type-2 (NF2) in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, and China.

The Neurofibromatosis Type-2 market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted Neurofibromatosis Type-2 market Size from 2017 to 2030, segmented by G-8 major markets. The report also covers the current Neurofibromatosis Type-2 treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying market potential.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
• China

Study Period: 2017–2030

Neurofibromatosis Type-2: Disease Understanding and Treatment Algorithm

Neurofibromatosis Type-2 Overview

Neurofibromatosis type 2 (NF2) is a rare genetic autosomal dominant, neurological, and neurodegenerative, tumor predisposition condition that results in slow-growing typically benign tumors, primarily located in the central nerve system (CNS); brain, and spinal cord. Clinical NF2 follows a genetic alteration to the NF2 gene, which disrupts the function of a cell membrane-related protein, merlin. Though the role of merlin is incompletely understood, it acts as tumor-suppressive by affecting multiple signaling pathways important for contact inhibition, cellular proliferation, and cellular growth.

The NF2 has a bimodal age of onset in children and young adults, with the former tending to present as severe phenotype with multiple tumors. Correspondingly, the clinical presentation of NF2 is grouped into two main subtypes: the more aggressive Wishart type is common for childhood-onset, and the less aggressive Gardner type-presenting in adulthood.

NF2 may lead to the most common clinical manifestations include bilateral vestibular schwannoma (VS), intracranial, and spinal tumors (schwannomas, meningiomas, and ependymomas), peripheral neuropathy, cataracts, and cutaneous tumors. Adults tend to present with symptoms of tinnitus, hearing loss, and/or imbalance related to VS, while children have symptoms due to spinal cord compression or other CNS-tumors, as well as ophthalmologic involvement.

The diagnosis is made based on the presence of specific clinical features. Under the NIH diagnostic criteria, a patient can be diagnosed with NF2 if they have bilateral VS or have a family history significant for NF2 and any one of the following: unilateral VS, another schwannoma, meningioma, glioma, neurofibroma, or juvenile posterior subscapular lens opacity. Refinements to the diagnostic criteria of NF2 have been proposed over time due to increasing understanding of clinical and molecular data. Large-population studies have demonstrated that some features, such as the development of gliomas and neurofibromas, currently included as diagnostic criteria, may require further clarification and modification.

Multidisciplinary management is required in patients with NF2, including oncologists, neurologists, neuroradiologists, ophthalmologists, geneticists, and neurosurgeons. For tumor surveillance, an annual brain MRI is recommended. Small asymptomatic vestibular schwannomas can be managed conservatively with MRI follow-up. Surgery is the primary treatment for large symptomatic vestibular schwannomas. Meningiomas are also treated surgically with radiation treatment reserved for non-surgical candidates. The spinal cord ependymomas are usually low-grade tumors and can be followed clinically with surgery reserved for symptomatic patients. Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), is new systemic immunotherapy for a wide range of tumors. Multiple studies have shown tumor regression and hearing improvement in NF2 patients treated with bevacizumab.

Neurofibromatosis Type-2 Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the Neurofibromatosis Type-2 market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, Japan, and China.

The DelveInsight Neurofibromatosis Type-2 market report gives a thorough understanding of Neurofibromatosis Type-2 by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides the treatment algorithms and treatment guidelines for Neurofibromatosis Type-2 in the US, Europe, Japan, and China.

Neurofibromatosis Type-2 Epidemiology

The Neurofibromatosis Type-2 epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every G-8 major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical and forecasted Neurofibromatosis Type-2 epidemiology segmented as the total diagnosed prevalent cases of Neurofibromatosis Type-2, age-specific cases of Neurofibromatosis Type-2, and tumor-specific cases of Neurofibromatosis Type-2. The report includes the prevalent scenario of Neurofibromatosis Type-2 symptoms in the G-8 covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China from 2017 to 2030.

Country-wise Neurofibromatosis Type-2 Epidemiology

The epidemiology segment also provides the Neurofibromatosis Type-2 epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China.

The total diagnosed prevalence population of Neurofibromatosis Type-2 in the G-8 countries were 59,274 cases in 2020.

Neurofibromatosis Type-2 Drug Chapters

The drug chapter segment of the Neurofibromatosis Type-2 report encloses the detailed analysis of Neurofibromatosis Type-2 marketed drugs and late stage (Phase-II and Phase-I/II) pipeline drugs. It also helps to understand the Neurofibromatosis Type-2 clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Currently, available treatments are non-curative. Despite the high morbidity associated with NF2 in severe cases, management of NF2-associated lesions primarily consists of surgical resection and treatment of symptoms.

Surgery can be used to remove most tumors, although it carries a risk of causing problems, such as complete deafness or facial weakness. Therefore, the risks and potential benefits need to be carefully considered before treatment. Small asymptomatic vestibular schwannomas can be managed conservatively with MRI follow-up. Surgery is the primary treatment for large symptomatic vestibular schwannomas. Also, localized radiation therapy is sometimes used for vestibular schwannomas, however, may risk the person’s hearing capacity as like surgery. Most people with NF2 eventually develop significant hearing loss and often benefit from using a hearing aid or learning to lip read. Special implants can sometimes be inserted to improve a person’s hearing. NF2 tends to get worse over time, although the speed at which this happens varies considerably.

Bevacizumab (Genentech) is a VEGF inhibitor, which prevents the interaction of VEGF to its receptors (Flt-1 and KDR) and inhibits cell proliferation and new blood vessels. Intravenous chemotherapy with Bevacizumab has been introduced in the last decade as one of the treatment options for NF2 patients. It is recommended for patients who have evidence of tumor progression and are considered poor candidates for surgery and radiotherapy. The drug has shown tumor shrinkage and hearing improvement. Following that, several studies reported the influence of Bevacizumab to decrease tumor volume and improve the hearing response in NF2 patients. Although the existing evidence supporting the use of Bevacizumab as a medical therapy is not stronger than level 3, the drug is in the extensive usage throughout the G-8 countries.

Products detail in the report…

Neurofibromatosis Type-2 Emerging Drugs

The MEK inhibitor-Selumetinib (AstraZeneca) regulate the extracellular signal-related kinase (ERK) pathway. This is the first-ever therapy to approved neurofibromatosis type 1 in the US and planning to enter the EU market. As per AstraZeneca, the drug has the potential to be expanded to all the neurofibromatosis types. Currently, the company is conducting phase II clinical studies for evaluating Selumetinib in patients with neurofibromatosis type 2 related tumors. By considering all these factors, the drug is expected to reach the US market by 2025 and drive future generation researches.

The mTOR inhibitor- Everolimus (Novartis) is already available in the market for multiple cancer indications and conducted clinical studies with progressive VS in NF2 patients. Even though, the trail did not meet the primary endpoint, evidence suggesting the potential to stabilize or delay tumor growth. To confirm the same, another phase II trial is evaluating the Everolimus as monotherapy in the treatment of Neurofibromatosis Type 2 - related vestibular schwannoma. The positive results from this trial may help the drug to reach the market by 20XX.

Products detail in the report…

Neurofibromatosis Type-2 Market Outlook

The Neurofibromatosis Type-2 market outlook of the report builds a detailed comprehension of the historical, current, and forecasted Neurofibromatosis Type-2 market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Neurofibromatosis Type-2 market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Neurofibromatosis Type-2 market in the G-8 is expected to change in the study period 2017–2030.

Increased understanding of the clinical manifestations of neurofibromatosis type 2 in conjunction with improved precision of genetic tests and imaging studies has improved the early diagnosis of patients. Further insight into the molecular pathogenesis and natural history of lesions along with advances in treatment and restorative modalities, will lead to improved management as well as advancements in clinical therapeutics

Key Findings

This section includes a glimpse of the Neurofibromatosis Type-2 market in the G-8. The market size of Neurofibromatosis Type-2 in the G-8 was found to be USD 188.09 Million in 2020.

The United States: Market Outlook

This section provides the total Neurofibromatosis Type-2 market size and market size by therapies of Neurofibromatosis Type-2 in the United States.

The United States accounts for the highest market size of Neurofibromatosis Type-2 in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain), Japan, and China.

Surgical resection is the mainstay for growing tumors but comes at the cost of significant morbidity, while radiotherapy is generally not advisable due to the risk of secondary malignancy and malignant transformation. Hence, there remains a critical demand for effective anti-neoplastic therapies for NF2-related tumors.

There is a lack of systemic therapies that address the underlying biology of the syndrome. Since NF2-related tumors tend to be slow-growing, options such as cytotoxic chemotherapies are not appropriate to treat this lifelong condition. Thus, molecularly targeted therapies represent a better treatment modality and a budding and encouraging prospect.

At present, international studies have found that some drugs can effectively control or even reduce the size of tumors. At present, the world has begun to use drugs to treat NF2 tumors. Reduce tumor volume and control tumor growth through oral or intravenous injection of drugs has been observed with the use of Bevacizumab.

EU-5 Countries: Market Outlook

The total Neurofibromatosis Type-2 market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are also mentioned.

Japan Market Outlook

The total Neurofibromatosis Type-2 market size and market size by therapies of Neurofibromatosis Type-2 in Japan are also mentioned.

China Market Outlook

The total Neurofibromatosis Type-2 market size and market size by therapies of Neurofibromatosis Type-2 in China are also mentioned.

Neurofibromatosis Type-2 Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017–2030. The analysis covers Neurofibromatosis Type-2 market uptake by drugs, patient uptake by therapies, and sales of each drug. 

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Neurofibromatosis Type-2 Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II and Phase I/II stage. It also analyses Neurofibromatosis Type-2 key players involved in developing targeted therapeutics.

Major players include Selumetinib (AstraZeneca), Bevacizumab (Genentech), Axitinib (Pfizer), Brigatinib (Takeda), AZD2014 (AstraZeneca), Everolimus (Novartis), AR-42/ REC-2282 (Recursion Pharmaceuticals), and others. The key products are expected to get launched in the US market by 20XX.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Neurofibromatosis Type-2 emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SME’s opinion working in the Neurofibromatosis Type-2 domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Neurofibromatosis Type-2 market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the Neurofibromatosis Type-2 market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers the descriptive overview of Neurofibromatosis Type-2, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
• Comprehensive insight has been provided into the Neurofibromatosis Type-2 epidemiology and treatment in the G-8.
• Additionally, an all-inclusive account of both the current and emerging therapies for Neurofibromatosis Type-2 is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the Neurofibromatosis Type-2 market; historical and forecasted, is included in the report, covering drug outreach in the G-8
• The report provides an edge while developing business strategies by understanding trends shaping and driving the global Neurofibromatosis Type-2 market

Report Highlights

• In the coming years, the Neurofibromatosis Type-2 market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Neurofibromatosis Type-2 R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for Neurofibromatosis Type-2. The launch of emerging therapies will significantly impact the Neurofibromatosis Type-2 market
• A better understanding of disease pathogenesis will also contribute to developing novel therapeutics for Neurofibromatosis Type-2.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competitor, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Neurofibromatosis Type-2 Report Insights

• Patient Population
• Therapeutic Approaches
• Neurofibromatosis Type-2 Pipeline Analysis
• Neurofibromatosis Type-2 Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Neurofibromatosis Type-2 Report Key Strengths

• 11-years Forecast
• G-8 Coverage
• Neurofibromatosis Type-2 Epidemiology Segmentation
• Key Competitors
• Highly Analyzed Market
• Drugs Uptake

Neurofibromatosis Type-2 Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Questions

Market Insights:

• What was the Neurofibromatosis Type-2 Market share (%) distribution in 2017, and how would it look like in 2030?
• What would be the Neurofibromatosis Type-2 total market Size and market Size by therapies across the G-8 during the forecast period (2017–2030)?
• What are the key findings pertaining to the market across G-8, and which country will have the largest Neurofibromatosis Type-2 market Size during the forecast period (2017–2030)?
• At what CAGR, the Neurofibromatosis Type-2 market is expected to grow in the G-8 during the forecast period (2017–2030)?
• What would be the Neurofibromatosis Type-2 market outlook across the G-8 during the forecast period (2017–2030)?
• What would be the Neurofibromatosis Type-2 market growth till 2030, and what will be the resultant market Size in the year 2030?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What are the disease risk, burden, and unmet needs of the Neurofibromatosis Type-2?
• What is the historical Neurofibromatosis Type-2 patient pool in G-8 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China?
• What would be the forecasted patient pool of Neurofibromatosis Type-2 in G-8 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China?
• What will be the growth opportunities in the G-8 with respect to the patient population pertaining to Neurofibromatosis Type-2?
• Out of all G-8 countries, which country would have the highest prevalent population of Neurofibromatosis Type-2 during the forecast period (2017–2030)?
• At what CAGR the population is expected to grow in the G-8 during the forecast period (2017–2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the treatment of Neurofibromatosis Type-2?
• What are the current treatment guidelines for treating Neurofibromatosis Type-2 in the USA, Europe, Japan, and China?
• What are the Neurofibromatosis Type-2 marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
• How many companies are developing therapies for the treatment of Neurofibromatosis Type-2?
• How many therapies are developed by each company for the treatment of Neurofibromatosis Type-2?
• How many emerging therapies are in the mid-stage and late stages of development for the treatment of Neurofibromatosis Type-2?
• What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Neurofibromatosis Type-2 therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Neurofibromatosis Type-2 and their status?
• What are the key designations that have been granted for the emerging therapies for Neurofibromatosis Type-2?
• What are the global historical and forecasted market for Neurofibromatosis Type-2?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the Neurofibromatosis Type-2 market
• To understand the future market competition in the Neurofibromatosis Type-2 market and Insightful review of the key market drivers and barriers.
• Organize sales and marketing efforts by identifying the best opportunities for Neurofibromatosis Type-2 in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), Japan, and China.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for the Neurofibromatosis Type-2 market.
• To understand the future market competition in the Neurofibromatosis Type-2 market.